<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1710">
  <stage>Registered</stage>
  <submitdate>12/10/2007</submitdate>
  <approvaldate>12/10/2007</approvaldate>
  <nctid>NCT00543712</nctid>
  <trial_identification>
    <studytitle>A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)</studytitle>
    <scientifictitle>A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>APM4171g</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chondrosarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PRO95780

Treatment: drugs: PRO95780
Intravenous repeating dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in vital signs before and after PRO95780 infusions; clinical laboratory evaluations</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Objective response</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of objective response</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Ability to understand and willingness to sign a written informed consent document

          -  Age = 18 years

          -  Histologic diagnosis of chondrosarcoma, verifiable after enrollment

          -  Measurable disease

          -  Previously treated or incurable disease without options for standard of care therapy

          -  ECOG performance status of 0-2

          -  Life expectancy of &gt; 3 months

          -  For patients of reproductive potential (males and females), use of reliable means for
             contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier)
             throughout the trial and for 1 year following their final exposure to study treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Systemic therapy or radiotherapy within 4 weeks prior to Day 1

          -  Prior therapy with agents targeting the DR5 apoptosis pathway

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks
             prior to Day 1, or anticipation of need for major surgical procedure during the course
             of the study

          -  Other invasive malignancies within 5 years prior to Day 1

          -  Known active brain metastases

          -  Uncontrolled intercurrent illness, including but not limited to ongoing or active
             infection requiring parenteral antibiotics at enrollment

          -  Clinically significant, symptomatic cardiovascular disease, New York Heart Association
             (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia, Grade
             II or greater peripheral vascular disease, or history of major heart surgery within 6
             months of Day 1, or any situation that would likely limit compliance with study
             requirements

          -  Known to be positive for hepatitis C or hepatitis B surface antigen

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates use of an investigational drug or that might affect interpretation of
             the results of the study or render the patient at high risk for treatment
             complications

          -  Use of anticoagulation therapy

          -  Participation in clinical trials or undergoing other investigational procedures within
             30 days prior to Day 1

          -  Pregnancy or breast feeding

          -  Known sensitivity to any of the products administered during the study

          -  Any disorder that compromises the ability of the patient to give written informed
             consent and/or comply with study procedures</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>3002 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and
      safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up
      to 90 patients with confirmed chondrosarcoma will be enrolled.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00543712</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sandra Skettino, M.D.</name>
      <address>Genentech, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>